Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity

NCT02918279 on ClinicalTrials.gov · last registry update 2020-04-27

Finished 14 February 2019, after enrolling 251 people. Primary outcome, as filed: Change in BMI SDS (Week 0, Week 56). liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 251
Started: 2016-09-29
Primary completion: 2019-02-14 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in BMI SDS (Week 0, Week 56)

Conditions studied

Metabolism and Nutrition Disorder · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.